Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of dataMarket Watch • 09/08/23
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall StreetThe Motley Fool • 09/06/23
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile InfectionGlobeNewsWire • 09/05/23
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks AgainThe Motley Fool • 08/30/23
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion CompoundsGlobeNewsWire • 08/08/23
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/08/23
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic ScholarshipsGlobeNewsWire • 07/26/23
Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven BlueprintSeeking Alpha • 07/17/23